OBJECTIVE: This cross-sectional study explored the association between carotid intima—media thickness (CIMT) and the oxidative stress markers asymmetric dimethylarginine (ADMA) and homocysteine in patients with end-stage renal disease who were on haemodialysis. METHODS: A total of 30 patients undergoing chronic haemodialysis treatment were recruited to this study. Homocysteine and ADMA levels were determined using a fluorescence polarization immunoassay and an enzyme-linked immunosorbent assay, respectively. CIMT was measured as a marker of atherosclerosis using high-resolution ultrasonography and was performed after haemodialysis. RESULTS: Significant positive correlations were found between CIMT and ADMA, and CIMT and duration of haemodialysis. Linear regression analysis showed that ADMA level and age were significant independent determinants of CIMT, whereas homocysteine was not. CONCLUSIONS: The relationship demonstrated between plasma ADMA and carotid artery thickening suggests that ADMA may be a novel marker of atherosclerosis in patients on haemodialysis.
KochMGradausFSchoebelFC: Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol Dial Transplant1997; 12: 1187–1191.
2.
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis2002; 39 (2 suppl 1): S1–S266.
3.
GuerinAPannierBLondonG: Atherosclerosis versus arterial stiffness in advanced renal failure In: Atherosclerosis, Large Arteries and Cardiovascular Risk (SafarMEFrohlichED eds). New York: Karger, 2007; pp 187–198.
4.
K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis2003; 41 (4 suppl 3): S1–S91.
5.
GibbonsGDzauV: The emerging concept of vascular remodeling. N Engl J Med1994; 330: 1431–1438.
6.
LondonGMMarchaisSJGuerinAP: Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant2002; 17: 1713–1724.
7.
LevinNWHandelmanGJCoreshJ: Reverse epidemiology: A confusing, confounding, and inaccurate term. Semin Dial2007; 20: 586–592.
8.
BleyerAJHartmanJBrannonPC: Characteristics of sudden death in hemodialysis patients. Kidney Int2006; 69: 2268–2273.
9.
MayerBZittaSGreilbergerJ: Effect of hemodialysis on the antioxidative properties of serum. Biochim Biophys Acta2003; 1638: 267–272.
10.
MorenaMCristolJPBoscJY: Convective and diffusive losses of vitamin C during haemodiafiltration session: A contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant2002; 17: 422–427.
11.
ShishehborMOliveiraLLauerM: Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol2008; 101: 1741–1746.
12.
ZimmermannJHerrlingerSPruyA: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int1999; 55: 648–658.
13.
ZoccaliCBenedettoFMallamaciF: Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens2000; 18: 1207–1213.
14.
BurkeGLEvansGWRileyWA: Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke1995; 26: 386–391.
15.
RaitakariOTJuonalaMKähönenM: Cardiovascular risk factors in childhood and carotid artery intima—media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA2003; 290: 2277–2283.
16.
DijkJMvan der GraafYBotsML: Carotid intima—media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study. Eur Heart J2006: 27: 1971–1978.
17.
HojsR: Carotid intima—media thickness and plaques in hemodialysis patients. Artif Organs2000; 24: 691–695.
18.
KawagishiTNishizawaYKonishiT: High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int1995; 48: 820–826.
19.
LondonGMGuerinAPMarchaisSJ: Cardiac and arterial interactions in end-stage renal disease. Kidney Int1996; 50: 600–608.
20.
KielsteinJTFliserD: The past, presence and future of ADMA in nephrology. Nephrol Ther2007; 3: 47–54.
21.
KielsteinATsikasDGallowayG: Asymmetric dimethylarginine (ADMA)–a modulator of nociception in opiate tolerance and addiction?Nitric Oxide2007; 17: 55–59.
22.
WeidingerFMcLenachanJCybulskyM: Persistent dysfunction of regenerated endothelium after balloon angioplasty of rabbit iliac artery. Circulation1990; 81: 1667–1679.
23.
MasudaHGotoMTamaokiS: Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol1999; 126: 211–218.
24.
ThumTTsikasDSteinS: Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol2005; 46: 1693–1701.
25.
BögerRH: Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med2005; 10 (suppl 1): S19–S25.
26.
SchulzeFWesemannRSchwedhelmE: Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med2004; 42: 1377–1383.
27.
ThahaMYogiantoroMTominoY: Intravenous N-acetylcysteine during haemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease. Clin Drug Investig2006; 26: 195–202.
28.
ThahaMWidodoPranawaW: Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine levels in end-stage renal disease patients. Clin Nephrol2008; 69: 24–32.
29.
BerglundGL: Ultrasound in clinical trials in atherosclerosis. Introduction. J Intern Med1994; 236: 551–553.
30.
PoliATremoliEColomboA: Ultrasonographic measurement of the common carotid artery wall thickness in hypercholesterolemic patients. A new model for the quantitation and follow-up of preclinical atherosclerosis in living human subjects. Atherosclerosis1988; 70: 253–261.
31.
DursunBDursunESuleymanlarG: The effect of hemodialysis on accelerated atherosclerosis in diabetic patients: correlation of carotid artery intima-media thickness with oxidative stress. J Diabetes Complications2009; 23: 257–264.
32.
DursunBDursunESuleymanlarG: Carotid artery intima—media thickness correlates with oxidative stress in chronic haemodialysis patients with accelerated atherosclerosis. Nephrol Dial Transplant2008; 23: 1697–1703.
33.
KraśniakADrozdzMPasowiczM: Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant2007; 22: 515–521.
34.
AndersonTGerhardMMeredithI: Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol1995; 75: 71B–74B.
35.
CelermajerD: Endothelial dysfunction: does it matter? Is it reversible?J Am Coll Cardiol1997; 30: 325–333.
BögerRBode-BögerS: Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Semin Thromb Hemost2000; 26: 539–545.
41.
CastelliW: Epidemiology of coronary heart disease: the Framingham study. Am J Med1984; 76: 4–12.
42.
HarrisonD: Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest1997; 100: 2153–2157.
43.
KannelW: Hypertension, blood lipids, and cigarette smoking as co-risk factors for coronary heart disease. Ann NY Acad Sci1978; 304: 128–139.
44.
LevineGKeaneyJVitaJ: Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med1995; 332: 512–521.
45.
NorenbergDD: Lipid Research Clinics Program. JAMA1984; 252: 2545.
46.
BlackwellS: The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem2010; 47: 17–28.
47.
SchulzeFLenzenHHanefeldC: Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J2006; 152: 493.e1–493.e8.
48.
KielsteinJSimmelSBode-BögerS: Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res2004; 27: 143–147.
49.
KielsteinJTImpraimBSimmelS: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation2004; 109: 172–177.
50.
VanholderRDe SmetSGlorieuxG: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int2003; 63: 1934–1943.
51.
KielsteinJTBögerRHBode-BögerSM: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol2002; 13: 170–176.
52.
KielsteinJTBögerRHBode-BögerSM: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol1999; 10: 594–600.
53.
VallancePLeoneACalverA: Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet1992; 339: 572–575.
54.
KielsteinJTBode-BögerSMFrölichJC: Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int Suppl2001; 78: S9–S13.
55.
HandMHaynesWWebbD: Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int1998; 53: 1068–1077.
56.
JoannidesRBakkaliEHLe RoyF: Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis. Nephrol Dial Transplant1997; 12: 2623–2628.
57.
KariJDonaldAVallanceD: Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int1997; 52: 468–472.
58.
FurukiKAdachiHMatsuokaH: Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima—media thickness of the carotid artery: an epidemiological study. Atherosclerosis2007; 191: 206–210.
59.
ZoccaliCBenedettoFARenkemaas: Asymmetric dimethylarginine, C-reactive protein, and carotid intima—media thickness in end-stage renal disease. J Am Soc Nephrol2002; 13: 490–496.
60.
ZoccaliCMallamaciFMaasR: Left ventricular hypertrophy cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int2002; 62: 339–345.
MeinitzerASeelhorstUWellnitzB: Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (The Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem2007; 53: 273–283.
63.
SchnabelRBlankenbergSLubosE: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease. Circ Res2005; 97: e53–e59.
64.
ZoccaliCBode-BögerSMallamaciF: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet2001; 358: 2113–2117.
